{"paper_id":"1e804a55-19f1-447d-9685-59e62333d325","body_text":"The evaluation of pharmacotherapy in endometriosis: changes, challenges and difficulties\nAbstract\nObjectives: Endometriosis presents a multitude of challenges for individuals. Current treatment of the disease is based on pharmacotherapy that aims to relieve pain, improves future fertility, potentially slows disease progression and lessen the likelihood of recurrence. The present review outlines recent reports on the importance of Gonadotropin-Releasing Hormone antagonists/antagonists and a new prospective as a significant second-line treatment option.\nMaterial and methods: A review of the literature from the last 5 years was conducted. The search included the following medical subject: “endometriosis”, “GnRh agonists”, “GnRh antagonists”, \"pharmacotherapy”. The articles published in English were included. Publications without full text access and duplicates were rejected.\nResults: Current research no longer focuse exclusively on finding new GnRH agonists/antagonists, but rather on maximizing their usage, in favour of the latter ones. Multiple active substances are now being combined into one tablet, which makes it easier for patients to take their medication and improves their adherence to treatment recommendations. 24 months monotherapy of linzagolix did not indicate any clinically relevant impact on overall bone condition in comparison to placebo group. Relugolix combination therapy-maintained bone mass density over two years while effectively alleviating pain symptoms.\nConclusions: Despite being effective, all treatments may have additional negative effects. The best approach to pharmacotherapy depends on the individual patient’s needs and circumstances. Taking into consideretion potential effects, an appropriate dose or a combination of the above options should be performed. The treatment options of Relugolix and Linzagolix are both promising and well-tolerated. Further research should focuse on long-term bone health monitoring strategies and its safety profile.\nKeywords: endometriosispharmacotherapyGnRh agonistshormonal treatmentGnRh antagonists\nReferences\n- King H. Hippocrates' woman: reading the female body in ancient Greece Routledge. London. 1998.\n- Stover Ed, Mercure E. The Pomegranate: A New Look at the Fruit of Paradise. HortScience. 2007; 42(5): 1088–1092.\n- Knapp VJ. How old is endometriosis? Late 17th- and 18th-century European descriptions of the disease. Fertil Steril. 1999; 72(1): 10–14.\n- Nezhat C, Nezhat F, Nezhat C. Endometriosis: ancient disease, ancient treatments. Fertil Steril. 2012; 98(6 Suppl): S1–62.\n- Brosens I, Benagiano G. History of Endometriosis: A 20th‐Century Disease. Endometriosis. 2012: 1–18.\n- Sampson J. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. American Journal of Obstetrics and Gynecology. 1927; 14(4): 422–469.\n- Kistner R. The Treatment of Endometriosis by Inducing Pseudopregnancy with Ovarian Hormones. Fertility and Sterility. 1959; 10(6): 539–556.\n- Ashfaq S, Pellegrini MV, Can AS. Danazol. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. ; 2025: Jan.\n- Barbieri RL, Evans S, Kistner RW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril. 1982; 37(6): 737–746.\n- Obrycka P, Soczynska J, Gawelczyk W, et al. Endometriosis – hormones and treatment. Medical Journal of Cell Biology. 2024; 12(2): 54–60.\n- Greenblatt RB, Tzingounis V. Danazol treatment of endometriosis: long-term follow-up. Fertil Steril. 1979; 32(5): 518–520.\n- Li RR, Xi Q, Tao L, et al. A systematic review and Bayesian analysis of the adverse effects of dienogest. BMC Pharmacol Toxicol. 2024; 25(1): 43.\n- Caruso S, Cianci A, Iraci Sareri M, et al. Randomized study on the effectiveness of nomegestrol acetate plus 17β-estradiol oral contraceptive versus dienogest oral pill in women with suspected endometriosis‑associated chronic pelvic pain. BMC Womens Health. 2022; 22(1): 146.\n- Seo JW, Lee DY, Yoon BK, et al. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur J Obstet Gynecol Reprod Biol. 2017; 212: 9–12.\n- Chung Y, Shim J, Baek J, et al. Gene Expression Profiling and Pathway Analysis of the Effect of Dienogest on Ovarian Endometriosis: A Comparative Study. Yonsei Medical Journal. 2025; 66(11): 780.\n- Yu Qi, Zhang S, Li H, et al. Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study. J Womens Health (Larchmt). 2019; 28(2): 170–177.\n- Alonso A, Gunther K, Maheux-Lacroix S, et al. Medical management of endometriosis. Curr Opin Obstet Gynecol. 2024; 36(5): 353–361.\n- Piriyev E, Schiermeier S, Römer T. Hormonal Treatment of Endometriosis: A Narrative Review. Pharmaceuticals (Basel). 2025; 18(4).\n- Vercellini P, Vercellini P, Buffo C, et al. Update on Medical Treatment of Endometriosis: New Drugs or New Therapeutic Approaches? Gynecol Obstet Invest. 2025; 90(6): 535–559.\n- Słopień R, Męczekalski B. Aromatase inhibitors in the treatment of endometriosis. Prz Menopauzalny. 2016; 15(1): 43–47.\n- Ferrero S, Gillott DJ, Venturini PL, et al. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011; 9: 89.\n- Abushahin F, Goldman KN, Barbieri E, et al. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril. 2011; 96(4): 939–942.\n- Zhao Yi, Luan X, Wang Y. Letrozole combined with oral contraceptives versus oral contraceptives alone in the treatment of endometriosis-related pain symptoms: a pilot study. Gynecol Endocrinol. 2021; 37(1): 51–55.\n- Peitsidis P, Tsikouras P, Laganà AS, et al. A Systematic Review of Systematic Reviews on the Use of Aromatase Inhibitors for the Treatment of Endometriosis: The Evidence to Date. Drug Des Devel Ther. 2023; 17: 1329–1346.\n- Alshammari E. Routine prescription of calcium in immobile females receiving medroxyprogesterone to prevent osteoporosis/ ¬¬bone loss. J Adv Pharm Educ Res. 2020; 10(3): 155–9.\n- Resta C, Moustogiannis A, Chatzinikita E, et al. Gonadotropin-Releasing Hormone (GnRH)/GnRH Receptors and Their Role in the Treatment of Endometriosis. Cureus. 2023; 15(4): e38136.\n- Surrey ES. GnRH agonists in the treatment of symptomatic endometriosis: a review. F S Rep. 2023; 4(2 Suppl): 40–45.\n- Matsuo H, Baba Y, Nair RMG, et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971; 43(6): 1334–1339.\n- Gerhard I, Schindler AE, Bühler K, et al. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther. 1992; 14 Suppl A: 3–16.\n- Dunselman GAJ, Vermeulen N, Becker C, et al. European Society of Human Reproduction and Embryology. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014; 29(3): 400–412.\n- Barbieri F, Ryan J. Long-term management of endometriosis with gonadotropin-releasing hormone agonists and add-back therapy. Fertil Steril. 1995; 64(1): 1–10.\n- Servidoni AC, Martin Gd, Gaio Gd, et al. Efficacy of Dienogest Versus GnRH Agonists After Endometriosis Surgery: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2026; 33(4): 391–402.\n- Sadler Gallagher J, Feldman HA, Stokes NA, et al. The effects of gonadotropin-releasing hormone agonist combined with add-back therapy on quality of life for adolescents with endometriosis: a randomized controlled trial. J Pediatr Adolesc Gynecol. 2017; 30(2): 215–222.\n- Brown J, Pan A, Hart R. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database of Systematic Reviews. 2010.\n- Wang JYi, Zhang Y, Ding J. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research. J Clin Med Res. 2025; 17(6): 299–308.\n- Tjahyadi D, Riyadi AS, Nugrahani AD, et al. Potency of oral gonadotropin-releasing hormone antagonist as endometriosis-associated pain novel treatments: An updated meta-analysis of randomized controlled trials. Int J Reprod Biomed. 2025; 23(9): 671–688.\n- Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017; 377(1): 28–40.\n- Miller CE, Kim JH, Kroll R, et al. Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial. Am J Obstet Gynecol. 2024; 231(6): 630.e1–630.e13.\n- Xie J, Ni X, Huang Q, et al. Relugolix's impact on endometriosis-associated pain and quality of life: a meta-analysis of EHP-30 outcomes. Front Endocrinol (Lausanne). 2025; 16: 1650579.\n- As-Sanie S, Mackenzie SC, Morrison L, et al. Endometriosis: a review. JAMA. 2025; 334(1): 64–78.\n- Donnez J, Becker C, Taylor H, et al. Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3). Hum Reprod. 2024; 39(6): 1208–1221.\n- Keam SJ. Linzagolix: First Approval. Drugs. 2022; 82(12): 1317–1325.\n- Paszkowski T. Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis. Prz Menopauzalny. 2025; 24(2): 126–130.\n- Becker CM, Johnson NP, As-Sanie S, et al. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study. Hum Reprod. 2024; 39(3): 526–537.\n- Schweppe KW, Wynn RM. Endocrine dependency of endometriosis: an ultrastructural study. Eur J Obstet Gynecol Reprod Biol. 1984; 17(2-3): 193–208.\n- Flores VA, Vanhie A, Dang T, et al. Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis. J Clin Endocrinol Metab. 2018; 103(12): 4561–4568.\n- Zhang P, Wang G. Progesterone Resistance in Endometriosis: Current Evidence and Putative Mechanisms. Int J Mol Sci. 2023; 24(8).\n- Edi R, Cheng T. Endometriosis: Evaluation and Treatment. Am Fam Physician. 2022; 106(4): 397–404.\n- Di Spiezio Sardo A, Becker CM, Renner SP, et al. Management of women with endometriosis in the 21st century. Curr Opin Obstet Gynecol. 2025; 37(3): 149–157.\n- Harada T, Osuga Y, Suzuki Y, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022; 117(3): 583–592.\n- Taniguchi F, Fukui M, Osuga Y, et al. Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study. Trials. 2025; 26(1): 41.\n- Othman ER, Al-Hendy A, Mostafa R, et al. Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents. Int J Womens Health. 2024; 16: 309–321.\n- Viviano M, Benagiano G, Guo SW, et al. Why do oestrogens matter: systematic review and meta-analysis assessing GnRH antagonists, considering add-back therapy, for endometriosis-associated pain. Reprod Biomed Online. 2024; 49(4): 104321.\n- Carballo García A, Fernández Rísquez AC, Delgado García S, et al. Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review. Biomedicines. 2025; 13(8).\n- Buggio L, Dridi D, Barbara G, et al. Novel pharmacological therapies for the treatment of endometriosis. Expert Rev Clin Pharmacol. 2022; 15(9): 1039–1052.\n- Abrao MS, Surrey E, Gordon K, et al. Reductions in endometriosis-associated pain among women treated with elagolix are consistent across a range of baseline characteristics reflective of real-world patients. BMC Womens Health. 2021; 21(1): 246.\n- Rzewuska AM, Żybowska M, Sajkiewicz I, et al. Gonadotropin-Releasing Hormone Antagonists-A New Hope in Endometriosis Treatment? J Clin Med. 2023; 12(3).\n- Maculaitis MC, Kim R, Hunsche E, et al. Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States. Womens Health (Lond). 2025; 21: 17455057251331700.\n- Donnez J, Becker CM, Petraglia F, et al. Hormone therapy for intramural myoma-related infertility from ulipristal acetate to GnRH antagonist: a review. Reprod Biomed Online. 2020; 41(3): 431–442.\n- Patel S, Saxena B, Mehta P, et al. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy. Pharmaceuticals (Basel). 2024; 18(1).\n- Li W, Lin A, Qi L, et al. Immunotherapy: A promising novel endometriosis therapy. Front Immunol. 2023; 14: 1128301.\n- Dmowski WP. Immunological aspects of endometriosis. International Journal of Gynecology & Obstetrics. 2002; 50(S1).\n- Zhu L, Chen ZJ, Liu H, et al. Safety and efficacy of subcutaneous injection with HMI-115 versus placebo in endometriosis-associated pain in premenopausal women: a multicentre, double-blind, randomised, proof-of-concept phase 2 trial. The Lancet Obstetrics, Gynaecology, & Women's Health. 2025; 1(3): e174–e188.","source_license":"public-domain-us","license_restricted":false}